sb-258585 has been researched along with sertindole* in 1 studies
1 other study(ies) available for sb-258585 and sertindole
Article | Year |
---|---|
Antiproliferative activities of the second-generation antipsychotic drug sertindole against breast cancers with a potential application for treatment of breast-to-brain metastases.
Epidemiological observations have shown that schizophrenia patients after long-term drug treatment exhibited reduced tumor incidences. The potential anticancer effects of antipsychotic drugs are subsequently demonstrated. These drugs are of great interest as agents against untreatable brain metastases because of their ability to traverse the blood-brain barrier (BBB). Most drugs tested thus far are the first-generation antipsychotics (FGAs). But their clinical application may be limited due to high risks of deaths in elderly patients. There is an urgent need to find additional BBB-traversing anticancer agents with lower risks of deaths. In this work, we investigated antitumor activities of eight second-generation-antipsychotic (SGA) drugs, since they exhibit lower mortality rates than FGAs. We discovered that sertindole showed broad antiproliferative activities against seven cancer types including 29 cell-lines and exhibited potent effects toward breast cancer cell-lines, with half maximal concentration to inhibit proliferation by 50% (IC Topics: Antipsychotic Agents; Apoptosis; Autophagy; Body Weight; Brain Neoplasms; Breast Neoplasms; Caspase 3; Cell Line, Tumor; Cell Movement; Cell Proliferation; Female; Humans; Imidazoles; Indoles; Models, Biological; Organ Size; Piperazines; Receptors, Serotonin; Sulfonamides; Tumor Burden | 2018 |